Home > Media > Details
Angitia Biopharmaceuticals Announces Founder and CEO David Ke Has Been Appointed as an Honorary Professor by Hong Kong Baptist University

Dr. David Ke, Founder and CEO of Angitia, has been appointed as an Honorary Professor by Hong Kong Baptist University (HKBU) during the 9th Honorary Professorship Conferment Ceremony-cum-Seminar on October 10th, 2023. This distinction is a recognition of Dr. Ke’s career achievement in drug discovery and development for musculoskeletal diseases, and his contribution to the education of HKBU. Dr. Ke was invited to present Angitia’s most recent research entitled “Targeting WNT Signaling for Discovering and Developing Innovative Therapies for Bone Diseases” following the conferment ceremony. The presentation was focused on unmet medical needs for new drugs in treating serious bone diseases such as osteoporosis and osteogenesis imperfecta and reported Angitia’s most recent efforts in drug discovery and development for osteogenesis imperfecta. The presentation was well received and generated a great level of interest from the audience in continuing the research and development of new therapies for osteoporosis and osteogenesis imperfecta.

“It is envisaged that the University and the School of Chinese Medicine would benefit tremendously from your profound knowledge and experience, and would appreciate your advice and sharing of ideas on research, teaching, and learning,” stated in a letter to Dr. David Ke issued by Professor Ping-kong Alexander Wai, President and Vice-Chancellor of HKBU.

“I am humbled to be honored as an Honorary Professor of HKBU. I deeply appreciated HKBU for bestowing this great honor to me,” said David Ke. “I will continue to do my very best in supporting the research and education of HKBU”.

Conference report from HKBU:


Angitia is a clinical-stage biotechnology company focused on the discovery and development of breakthrough therapeutics that address the unmet medical needs of patients with serious musculoskeletal diseases. With the team’s experience and scientific expertise in novel drug development, Angitia is dedicated to bringing innovative therapies to help patients in need. Founded in 2018, Angitia has operations in Guangzhou, China and Woodland Hills, California, USA.

Learn more at and follow us on LinkedIn.

Forward-Looking Statement

This press release is prepared by Angitia (the “Company", “We”) for informational purposes only. Forward-looking statements include all statements that are not historical facts and in some cases can be identified by terms such as “anticipate,” “expect,” “intend”, “plan”, “believe”, “continue”, “could”, “potential”, “may”, “will”, “goal” or similar expressions and the negatives of those terms. However, not all forward-looking statements contain these identifying words.

These forward-looking statements are based on the current projects, expectations, assumptions, and understandings of the Company with respect to future events as of the date these statements are made. These statements are not a guarantee or warranty of future developments or otherwise.

These statements involve substantial known and unknown risks, uncertainties, and other factors that are beyond the Company’s control and are difficult to predict and may cause our actual results, timing of results, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We anticipate that subsequent events and developments may cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.

Except as expressly required by law, the Company and/or its officers, directors, employees, and agents shall not assume responsibility for the accuracy and completeness of the forward-looking statements in the information provided.